The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan

Research output: Contribution to journalArticlepeer-review

26 Citations (Scopus)

Fingerprint

Dive into the research topics of 'The real-world cost-effectiveness of adjuvant trastuzumab in HER-2/neu-positive early breast cancer in Taiwan'. Together they form a unique fingerprint.

Medicine and Dentistry